AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s product candidates DSUVIA, known as DZUVEO in Europe and Zalviso are both focused on the treatment of acute pain, and each utilize sufentanil, delivered via a non-invasive route of sublingual administration, exclusively for use in medically supervised settings. DSUVIA is indicates for use in adults in a certified medically supervised healthcare setting, such as hospitals, surgical centers and emergency departments for the management of acute pain severe enough to require an opioid analgesic. Zalviso is designed to help address certain problems associated with post-operative IV patient-controlled analgesia (PCA). Zalviso allows patients to self-administer sufentanil sublingual tablets via a pre-programmed, secure system designed in part to eliminate the risk of healthcare provider programming errors.